As most of the previously discovered small molecules targeting β-secretase and γ-secretase, have been failed in clinical trials, discovery of selective and potent DYRK1A inhibitors is an emerging research area for AD treatment [61,62,63,64]. The gene discussed is DYRK1A; the disease is Alzheimer disease.